42071-66-9

Upstream product

• 50-00-0 formaldehyd 
• 10342-83-3 4'-Bromopropiophenone 
• 92207-34-6 1-(4-bromophenyl)-3-hydroxy-2-methylpropan-1-one 
• 108-86-1 bromobenzene 
• 920-46-7 Methacryloyl chloride 
• 124-38-9 carbon dioxide 
• 1450-10-8 [1-(4-Brom-benzoyl)-aethyliden]-triphenyl-phosphoran 

Downstream Products

• 1396011-26-9 (R)-3-(benzylthio)-1-(4-bromophenyl)-2-methylpropan-1-one 

Relevant academic research and scientific papers

Transition-Metal-Free Reductive Deoxygenative Olefination with CO2

A new transition-metal-free reductive deoxygenative olefination of phosphorus ylides with CO2, an abundant and sustainable C1 chemical feedstock, is described. This catalytic CO2 fixation afforded β-unsubstituted acrylates and vinyl ketones in good yields with broad scope and good functional group tolerance under mild reaction conditions. Cost-effective and easily handled polymethylhydrosiloxane was used as a reductant. Bis(silyl)acetal was proved to be the key intermediate in this reductive functionalization of CO2.

PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME

The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

Thermal retro-aldol reaction using fluorous ether F-626 as a reaction medium

A high-boiling, fluorous-organic hybrid ether, F-626, was tested for use in thermal retro-aldol reactions and found to be an excellent reaction medium in view of the ease of separation from the product by fluorous/organic biphasic treatment. The recovered F-626 can be readily reused for subsequent runs.

Inotropic, vasodilator and low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) inhibitory activities of 4a-methyl-4,4a-dihydro-5H-indenopyridazin-3(2H)-ones and 4a-methyl-4,4a,5,6-tetrahydrobenzocinnolin-3(2H)-ones

Novel 7-substituted-4,4a-dihydro-4a-methyl-5H-indenopyridazin-3-ones and 8-substituted-4a-methyl-benzocinnolin-3-ones have been synthesized and their PDE III inhibitory, inotropic and vasodilator potencies compared with those of their normethyl analogues and their bicyclic 4,5-dihydro-6-phenylpyridazinone analogues.The structure-activity relationships of the tricyclic pyridazinones differ from those of bicyclic pyridazinones mainly in respect of the effect of introducing the methyl group into the pyridazinone ring.Whilst in the4,5-dihydro-6-phenylpyridazin-3(2H)-ones, introduction of a 5-methyl group has been widely reported to lead to compounds of significantly greater potency, the novel tricyclic 4a-methylpyridazinones showed similar levels of inotropic, vasodilator and PDE III inhibitory potency to their normethyl analogues.Possible reasons for this difference in behaviour are discussed.